Andrea Lobo, PhD, science writer —

ViaNautis has secured $25 million in financing to advance work with polyNaut, its delivery platform for genetic and other treatments. The platform is designed to deliver a range of therapies into difficult-to-penetrate tissues. According to the company, the money raised will help to support polyNaut’s use…

Six months of treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly improved lung function and nutritional status in two adults with cystic fibrosis (CF) caused by the rare mutation M1101K, according to two cases described in Canada. “Our cases not only demonstrate the therapeutic benefit of [Trikafta] in individuals with non-F508del…

The pediatric and adult cystic fibrosis programs at Geisinger Medical Center have received an award from the Cystic Fibrosis Foundation (CFF) for their work in improving the care of people with cystic fibrosis (CF). Given annually, the CFF’s Quality Improvement Award recognizes centers that work continuously to improve…

Kaftrio and Symkevi — marketed in the U.S. as Trikafta and Symdeko, respectively — may be effective in treating people with cystic fibrosis (CF) caused by rare mutations, according to a new study from the U.K. Both treatments were found to improve lung function and to ease…

Treatment with Kaftrio eased gastrointestinal symptoms in people with cystic fibrosis (CF), ages 12 and older, according to a real-world study in the U.K and Ireland. The treatment’s maximum effect was achieved after two months and included a decline in gut inflammation. The study, “Reduction in abdominal…

Electronic home monitoring using a spirometry device may help improve lung function in children with cystic fibrosis (CF), according to a recent study. Specifically, a standard measure of lung function called forced expiratory volume in one second (FEV1) was found significantly improved in children who used the device, compared…

Almost two years of treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor) did not affect liver stiffness — an indicator of liver fibrosis — in adults with cystic fibrosis (CF), according to a recent study in the U.K. However, patients with elevated markers of liver stiffness before starting on…

Inogen has acquired Physio-Assist, including Simeox, a technology for airway clearance and mucus management in people with cystic fibrosis (CF). The company will continue marketing Simeox in Europe, Asia, and the Middle East, while pursuing regulatory clearance in the U.S. This acquisition will expand Inogen’s portfolio of…

Infections with Staphylococcus aureus small colony variants, known as SCVs, are highly prevalent in people with cystic fibrosis (CF) — and linked to the previous use of the broad-spectrum antibiotic trimethoprim sulfamethoxazole, a systematic literature review has found. SCVs are slow-growing bacteria that are associated with higher rates of chronic…

An increase in body mass index (BMI) in people with cystic fibrosis (CF) under Kaftrio therapy may not be attributable to increased energy intake, according to a new U.K. study. Instead, gains in BMI, a measure of body fat, might reflect other factors, such as different energy requirements…